cyclo(sulfoalanyl-prolyl-valyl-leucyl-tryptophyl) has been researched along with s6c sarafotoxin in 1 studies
| Studies (cyclo(sulfoalanyl-prolyl-valyl-leucyl-tryptophyl)) | Trials (cyclo(sulfoalanyl-prolyl-valyl-leucyl-tryptophyl)) | Recent Studies (post-2010) (cyclo(sulfoalanyl-prolyl-valyl-leucyl-tryptophyl)) | Studies (s6c sarafotoxin) | Trials (s6c sarafotoxin) | Recent Studies (post-2010) (s6c sarafotoxin) |
|---|---|---|---|---|---|
| 9 | 0 | 0 | 595 | 3 | 37 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battistini, B; Cirino, M; Rodger, IW; Yano, M | 1 |
1 other study(ies) available for cyclo(sulfoalanyl-prolyl-valyl-leucyl-tryptophyl) and s6c sarafotoxin
| Article | Year |
|---|---|
Dual cardiovascular effects of endothelin-1 dissociated by BQ-153, a novel ETA receptor antagonist.
Topics: Animals; Cardiovascular System; Endothelin Receptor Antagonists; Endothelins; Female; Hemodynamics; Injections, Intravenous; Male; Peptides, Cyclic; Swine; Vasoconstrictor Agents; Viper Venoms | 1994 |